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A cDNA expression clone of the human malarial par-
asite Plasmodium falciparum, lPf4, which was reactive
only to the immune sera and not to the patient sera, has
recently been found to be the P. falciparum homologue
of the P0 ribosomal phosphoprotein gene. A Northern
analysis of the P0 gene revealed the presence of two
transcripts, both present in all the different intraeryth-
rocytic stages of the parasite life cycle. A 138-base pair
amino-terminal domain of this gene was expressed as a
fusion protein with glutathione S-transferase in Esche-
richia coli. Polyclonal antibodies raised against this do-
main immunoprecipitated the expected 38-kDa P0 pro-
tein from the 35S-labeled as well as 32P-labeled P.
falciparum cultures. Monospecific human immune sera
affinity-purified using the expression clone lPf4 also
immunoprecipitated the same size protein from [35S]me-
thionine-labeled P. falciparum protein extract. Purified
IgG from polyclonal antibodies raised against the ami-
no-terminal domain of P0 protein completely inhibited
the growth of P. falciparum in vitro. This inhibition
appears to be mainly at the step of erythrocyte invasion
by the parasites.
It has been documented that people living in malaria-en-
demic areas acquire immunity to Plasmodium falciparum after
repeated infections. The nature of this immunity is poorly
understood at the molecular level. It is apparent from studies
involving passive transfer of IgG from immune adults to the
non-immune subjects that circulating antibodies do play an
important role (1, 2). The specificity of these protective anti-
bodies is as yet unknown. It has been shown that the antibodies
present in immune adults recognize domains that are con-
served in different strains of P. falciparum (3). However, it has
also been documented that many malarial antigens possess
repetitive protein domains, which evoke a strong antibody re-
sponse. Many of these antibodies are non-protective, and the
corresponding malarial epitopes are postulated to be immune-
evasive or smokescreen domains (4, 5). Thus, to search for
pan-specific and possibly protective antibodies, a differential
immunoscreening of an erythrocytic stage-specific cDNA ex-
pression library of P. falciparum was carried out using malar-
ia-immune and acute patient sera. This resulted in the identi-
fication of several novel cDNA clones, which reacted exclusively
and yet extensively with immune sera samples (6). The clone
lPf4, which was reactive to the largest number of immune sera
(80 out of 92), has been cloned and sequenced recently (7). This
was found to be the P. falciparum gene homologue of the
ribosomal phosphoprotein P0 (PfP0).1
Ribosomal phosphoprotein P0 is considered to be related to
the family of the acidic ribosomal phosphoproteins P1 and P2,
because of the highly homologous carboxyl-terminal domain
(8). Antibodies against this domain coprecipitate all three P
proteins (9). P0 could be cross-linked to P1 and P2 protein in
Artemia salina ribosomes (10), and these data, along with that
from yeast cells (11), strongly indicate the existence of a
(P1)2zP0z(P2)2 protein complex in the eukaryotic ribosomes.
This complex has been compared with the bacterial complex
L10z(L7/L12)2, which forms the stalk of the large subunit at the
GTPase domain along with the 23 S ribosomal RNA (12, 13). It
has been documented that P0 protein is absolutely required for
the ribosomal activity and cell viability in yeast (14). The
conserved carboxyl-terminal domain of the P proteins is very
antigenic and found to be the main antigenic target for sera
reactivity of about 10–15% of patients of the autoimmune
disorder systemic lupus erythematosus (15). Antibodies to this
domain have also been detected in patients of suffering from
diseases caused by protozoan parasites such as Chagas’ heart
disease (16) and leishmaniasis (17). In this paper we report the
characterization of this protein from P. falciparum, and we
show for the first time that P0 is indeed a phosphoprotein. We
also show that antibodies raised against the amino-terminal
domain of this protein inhibits P. falciparum growth in vitro.
EXPERIMENTAL PROCEDURES
Materials—All reagents, unless otherwise specified, were purchased
from Sigma. [a-32P]dATP, [32P]orthophosphoric acid were provided by
the Board of Radiation Technologies, India. [35S]Methionine and
[35S]cysteine were purchased from Amersham International (Bucking-
hamshire, England).
Parasite Cultures—Asexual stages of FCR3 (Gambia) and the FCK2
(India) strains of P. falciparum were cultured in vitro at 37 °C in the
presence of human erythrocytes of serological type O1 in complete
medium (RPMI 1640 medium containing 28 mM NaHCO3, 25 mM
HEPES, and supplemented with either 10% human serum or 0.5%
Albumax (Life Technologies, Inc.) and 80 mg/ml Gentamycin sulfate) in
sterile Petri dishes using the candle-jar method or sealed flasks flushed
with 5% O2, 5% CO2, and 90% N2 gas mixture (18). For stage-specific
RNA preparation and in vitro parasite growth inhibition assays, cul-
tures were synchronized by sorbitol treatment according to the method
of Lambros and Vanderberg (19). Intracellular parasites from each of
the substages were liberated from infected erythrocytes by saponin lysis
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(20) for total RNA and genomic DNA extraction. The gametocytic stages
of the parasite (NF54 strain) used for the immunofluorescence studies
were kindly provided by Dr. Nirbhay Kumar, Johns Hopkins University
(21).
Preparation of Nucleic Acids—Total cellular RNA was extracted us-
ing a single step method described by Chomczynski and Sacchi (22).
Genomic DNA was extracted from total erythrocytic stages of the par-
asite as described in detail elsewhere (6).
Southern and Northern Hybridization—Southern and Northern hy-
bridization were performed with the radioactively labeled [a-32P]dATP
251-bp lPf4 cDNA fragment as well as the 700-bp L-4-7 (carboxyl-
terminal fragment of PfP0 protein) with specific activity of 2 3 108 cpm
by following the membrane manufacturer’s protocol (Amersham Inter-
national) in the presence of 50% formamide. Briefly, 2 mg of parasite
genomic DNA cut with appropriate restriction enzymes (New England
Biolabs Inc.) was electrophoresed in a 1.0% agarose gel. In the case of
Northern hybridization, total RNA from the parasite was electrophore-
sed in formaldehyde containing 0.8% agarose gel. 0.69–9.44-kb RNA
markers (Life Technologies, Inc.) were run and stained separately with
ethidium bromide before transfer of the gel onto the membrane. Gels
were transferred to Hybond N1 membrane (Amersham International)
by capillary blotting following membrane manufacturer’s protocol. Air-
dried blots were then UV cross-linked in a UV cross-linker (Bio-Rad) for
2 min and pre-hybridized at 42 °C for 2–3 h. Hybridization was carried
out at 42 °C for 18–20 h. Blots were washed twice at 65 °C for 15 min
each with 2 3 saline/sodium/phosphate/EDTA, 0.1% (w/v) SDS followed
by washes with 1 3 saline/sodium/phosphate/EDTA, 0.1% SDS and
0.1 3 saline/sodium/phosphate/EDTA, 0.1% SDS, and exposed to Fuji
x-ray film for autoradiography. The quantitation was performed using
the gel-documentation system (Ultraviolet Products Inc.) as per manu-
facturer’s protocol by estimating the volume of the signal.
Bacterial Expression of Amino-terminal Domain of P0 Protein as a
GST-fusion Protein—A GST reporter-based vector (pGEX-1) was used
as an expression vector (23). A HindIII-EcoRI restricted 138-bp amino-
terminal fragment of PfP0 (46–184 bp of GenBankTM accession number
U56663) (7) was flushed at both ends with Klenow and subcloned in
pGEX-1 restricted with SmaI. The Escherichia coli cells harboring the
vector pGEX-1 and the recombinant containing PFP0-N insert were
induced with 1 mM isopropyl-b-D-thiogalactopyranoside for 2 h at 37 °C
(23). The total cell lysates were run on a 12% denaturing SDS-poly-
acrylamide gel electrophoresis and stained with Coomassie Blue to
show the fusion protein (PfP0-N). The polyacrylamide gel piece contain-
ing the fusion protein band was cut out and crushed in liquid nitrogen
and dissolved in phosphate-buffered saline (8 g/liter NaCl, 0.2 g/liter
KCl, 1.44 g/liter Na2HPO4, 0.24 g/liter KH2PO4, pH adjusted to 7.4 with
NaOH). The resulting slurry containing an estimated amount of 100 mg
of protein was injected into two rabbits. Five boosts were given to each
animal to generate antibodies with reasonable titer (.1000 as checked
by enzyme-linked immunosorbent assay).
Preparation of Monospecific Human Sera—lPf4 cDNA clones in
lgt11, as well as wild type lgt11, were grown on E. coli strain Y1090 to
lytic phase (6). Hybond-C membrane (Amersham International) soaked
in isopropyl-b-D-thiogalactopyranoside was overlaid on these phage
plates and grown for an additional 12–16 h. The membranes were
washed three times with 1 3 TBS-T (200 mM Tris, 50 mM NaCl, 0.05%
Tween 20, pH 7.5). A pool of six reactive human immune sera (1:100
dilution) used for the differential immunoscreening (6) was first incu-
bated overnight at 4 °C with membrane saturated with the wild type
lgt11 lysate. Then the sera was incubated overnight with several mem-
branes containing the lysate of recombinant lPf4. Monospecific anti-
bodies against lPf4 were eluted with 5 mM glycine from the membrane,
neutralized with 1 M Tris, and then dialyzed overnight with three
changes of TBS-T. Resulting monospecific antibody solution against
lPf4 was concentrated using an Amicon concentrator (Amicon Inc.),
reconstituted to the original volume of the human sera with 1 3 TBS-T,
and used for immunoprecipitation.
Preparation of [35S]Methionine, [35S]Cysteine, and 32P-Labeled Pro-
teins from P. falciparum and Immunoprecipitation Studies—Asynchro-
nous cultures of P. falciparum containing 10–12% parasitemia were
washed twice with methionine- and cysteine-free RPMI 1640 medium
and resuspended at a final hematocrit of 5% in the same medium
supplemented with 10% human serum. 100 mCi/ml of both radiolabeled
methionine and cysteine were added to the culture medium and incu-
bated for 4 h at 37 °C under normal culture conditions with occasional
shaking. After labeling, the cells were washed and extracted as de-
scribed elsewhere (24). In the case of 32P-labeling, 1 mCi/ml radiola-
beled orthophosphoric acid was neutralized using 1 N NaOH added to
the washed parasites at 5% hematocrit (about 10% parasitemia) in the
RPMI 1640 medium supplemented with 0.5% Albumax (Life Technolo-
gies, Inc.), incubated for 4 h at 37 °C, and the rest of the steps were the
same as above. Monospecific human immune sera against lPf4 as well
as rabbit polyclonal antibody against PfP0-N were used to precipitate
the 35S- and 32P-labeled parasite proteins (24). The immunoprecipitated
samples were run on 12% denaturing gels, which were stained with
Coomassie Blue for 1 h and destained with destaining solution (30%
methanol, 10% acetic acid) for 2 h. 35S-Containing gels were soaked
with 1M sodium salicylate for 30 min and washed with water for another
30 min. In the case of 32P-containing gels, the destaining was continued
overnight with several changes of the destaining solution. The gels were
then dried using Gel dryer (Hoefer Scientific Co.) and exposed to Fuji
x-ray film for autoradiography.
Indirect Immunofluorescence Assay (IFA)—IFA studies were done
with P. falciparum asexual (FCR3 strain) as well as gametocytic stages
(NF54 strain) with polyclonal antibodies against PfP0-N as described
earlier (25). Briefly, asynchronous asexual and sexual stage cultures of
P. falciparum were coated on glass slides as smears and air dried for
overnight. The slides were fixed with methanol for 30 s at room tem-
perature, blocked with 100 mg/ml bovine serum albumin solution for
2–3 h at room temperature, and washed at room temperature with 1 3
TBS-T for 10 min each for three times. Slides were incubated with
respective antibodies for 3–4 h at room temperature. FITC-conjugated
anti-rabbit IgGs (Cappel, Organon Teknika, Durham, NC) at 1:80 di-
lution were used as the secondary antibody. The slides were observed
under a Zeiss (Axioplan) microscope using 3 100 Neofluor phase con-
trast objective and Zeiss filter FT500/600. All antibodies were cleared
with GST and E. coli crude proteins and used at 1:100 dilution.
In Vitro Inhibition of P. falciparum Growth—IgG from rabbit sera
were purified by ammonium sulfate precipitation followed by batch
purification with DEAE-cellulose at pH 6.5 (26). P. falciparum growth
inhibition assays were performed in triplicates in 24-well sterilized
tissue culture plates (Nunc, Roskilde, Denmark) in a total culture
volume of 1 ml. The effect of IgG on parasite growth was assessed by
starting with ring stage-synchronized parasites at a 0.2–0.5% initial
parasitemia and monitoring growth over 48 h without any medium
replacement. Blood mononuclear cells from healthy donors were sepa-
rated on Ficoll-Hypaque density gradient (Pharmacia Biotech Inc.). The
adherent monocytes were selected in 24-well plates and counted (2). In
the wells containing the adherent monocytes, P. falciparum cultures
were added at a ratio of approximately 200 red blood cells/monocyte.
Control wells consisted of (a) culture alone, (b) culture and monocytes
alone, (c) culture and control IgG, and (d) culture, control IgG, and
monocytes. Test and control IgG were added at a concentration of
1.0–1.5 mg/ml of final culture volume. Parasitemia was monitored
every 6 h by preparing thin smear slides from each well and by micro-
FIG. 1. Southern blot analysis. Panel A, Southern blot analysis of
genomic DNA of the HB3 strain of P. falciparum cut with different
restriction enzymes (EcoRI (lane 1), ClaI (lane 2), DraI (lane 3), and
HaeIII (lane 4), respectively, and hybridized with radiolabeled 251-bp
lPf4 fragment. Panel B, Southern analysis of the same blot with radio-
labeled carboxyl-terminal L-4-7 fragment of P0, as described under
“Experimental Procedures.” The arrows indicate the two different
genomic EcoRI fragments containing the P0 gene.
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scopic examination of .10,000 red blood cells. In each experiment, the
number of rings, trophozoites, and schizonts were counted separately.
Total parasitemia was estimated as the sum total of the rings, tropho-
zoites, and schizonts.
RESULTS
A Southern blot of genomic DNA from the HB3 strain of P.
falciparum, probed with the 251-bp lPf4 insert, showed that it
hybridizes with the 6.1-, 13-, 1.5-, and 11-kilobase pair band
when the DNA was restricted with EcoRI, ClaI, DraI, and
HaeIII, respectively (Fig. 1, panel A). The gene has an internal
EcoRI site, and this was demonstrated by probing the same blot
with a 700-bp fragment, L-4-7, representing the carboxyl-ter-
minal part of the protein (7), which lit up the same bands for all
restriction digests except that of EcoRI, where it showed a
7.0-kilobase pair band (Fig. 1, panel B). Southern analysis of
genomic DNA from two other P. falciparum strains, FCR3 and
NF54, was also performed with these two probes, and no sig-
nificant restriction fragment length polymorphism was ob-
served. These results show that the PfP0 is coded by a single
gene and is well conserved in different strains of the parasite.
A Northern blot of stage-specific total RNA from the asexual
stages of P. falciparum, probed with the 251-bp lPf4 fragment,
showed a dominant 3.0-kb-size fragment in every substage
(Fig. 2). However, a second band, about 2.0 kb in size, was also
seen in all stages. A quantitative determination of the ratio of
these transcripts showed that the 3.0-kb message was 2.1 6
0.26-fold as abundant as the 2.0-kb message in each of the
stages. However, the 3.0-kb transcript was about 2.0- and
1.5-fold greater in abundance in the trophozoites compared
with the rings and the schizont stages, respectively. The coding
region of the P0 gene is 957 bp. However, the gene seems to
possess a long 59-untranslated region of about 1.4 kb in length,
as observed by the size of cDNA clones isolated (7). Polymerase
chain reaction studies using primer sequences within the cod-
ing region amplify the same size of fragments when genomic
DNA is used as a template (data not shown), and therefore,
there are no introns within the coding sequence. However, the
presence of introns in the 59-untranslated region is yet to be
determined.
FIG. 2. Northern blot analysis of total RNA from different in-
tra-erythrocytic stages of P. falciparum with radiolabeled lPf4.
Lane 1, 100% rings; lane 2, early trophozoites (20% rings, 50% early
trophozoites, 25% late trophozoites, and 5% schizonts); lane 3, late
trophozoites (60% late trophozoites and 40% early schizonts); lane 4,
schizonts (20% late trophozoites, 60% early schizonts, and 20% seg-
mented schizonts). An equal amount of total RNA (10 mg), as deter-
mined by the absorbance value at 260 nm, was loaded in each lane.
Arrows show the two P0 transcripts at 2.0 and 3.0 kb.
FIG. 3. Panel A, expression of the recombinant PfP0-N in E. coli as a
fusion protein with GST. Total lysates of E. coli induced with 1 mM
isopropyl-b-D-thiogalactopyranoside were run on a 12% SDS-polyacryl-
amide gel electrophoresis and stained with Coomassie Blue. Lysates of
cells transfected with lane 1 is the vector pGEX and lane 2 is the
recombinant-containing PfP0-N insert. The fusion protein GST-PfP0-N
is marked with an arrow. Panel B, immunoprecipitation studies using
immunoprecipitation of [35S]methionine, [35S]cysteine-labeled (lanes 1,
2, and 4), and 32P-labeled (lane 3) P. falciparum asexual stage proteins.
The antibodies used for immunoprecipitation were monospecific human
immune sera affinity-purified against wild type lgt11 (lane 1), mono-
specific human immune sera affinity-purified against lPf4 (lane 2), and
rabbit polyclonal antibodies against PfP0-N (lanes 3 and 4). The arrow
marks the 38-kDa P0 protein.
FIG. 4. IFA with rabbit anti-PfP0-N antibody-indirect immu-
nofluorescence assays of erythrocytic and gametocytic stages of
P. falciparum were performed with polyclonal antibodies
against PfP0-N. Panels A and B, the erythrocytic stages; panels C and
D, the gametocytic stages.
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Fig. 3A shows the expression of the GST-fusion protein of the
amino-terminal domain of the P. falciparum P0 protein
(PfP0-N) in the total E. coli cell lysate. The 46-amino acid
stretch (17–62 amino acids) from the 138-bp HindIII-EcoRI
fragment (7) produced the expected 31-kDa GST-fusion pro-
tein. Polyclonal rabbit antibodies, with a titer of .1000, were
raised against PfP0-N and used for immunoprecipitation, im-
munofluorescence, and growth inhibition studies.
This antibody immunoprecipitated a single 38-kDa phospho-
protein from the 35S- and 32P-labeled P. falciparum proteins
(Fig. 3B). Control antibodies such as rabbit preimmune sera
and rabbit polyclonal antibodies raised against GST did not
show any band (data not shown). To ascertain that the human
immune sera originally used for the differential screen actually
recognized the PfP0 protein domain in the lPf4 expression
clone, monospecific human immune sera was affinity-purified
using lPf4 expression clone and used for immunoprecipitation
analysis. This also brought down the 38-kDa P0 protein from
35S-labeled parasite proteins (Fig. 3B). Human immune sera
affinity-purified against the control phage lgt11 did not show
any reactivity with the parasite extract (Fig. 3B). Western blots
of the recombinant PfP0-N protein with immune and patient
sera samples showed that the recombinant protein was de-
tected only by immune sera samples and not by patient sera
samples (data not shown).
Rabbit antibodies raised against PfP0-N were used for IFA
studies with different asexual stages (Fig. 4, A and B) as well as
gametocytic stages of the parasite (Fig. 4, C and D). Rabbit
preimmune sera and polyclonal antibodies against GST were
used as control. The control antibodies showed no staining with
parasites, whereas the anti-PfP0 antibody showed staining
with all the different developmental stages of the parasite. In
some of the gametocytic stages, intense staining of some sub-
cellular domains were noticed (Fig. 4D), but the significance of
this observation is not clear. The localization of the antigen was
predominantly intracellular, however there appeared to be
some staining at the surface as well. Preliminary experiments
with biochemically fractionated parasite extracts do show an-
tibody reactivity to the particulate fractions on Western blots
(data not shown). When tested on Toxoplasma gondii, an api-
complexan parasite closely related to Plasmodium, it was ob-
served to stain the surface, as confirmed by double staining
with surface and internal markers of Toxoplasma.2
It has been reported that the protective human immune sera
inhibits the in vitro growth of P. falciparum only in the pres-
ence of monocytes (2). However, these experiments were per-
formed with mixed specificities of immunoglobulins. To ascer-
tain whether anti-PfP0 antibody inhibits the growth of P.
falciparum in the presence or absence of monocytes, in vitro
inhibition studies using synchronized parasites starting from
the ring stages were performed (Fig. 5). The antibodies raised
against PfP0-N completely inhibited the growth of the para-
sites over a 48-h period (Fig. 5, panel A). Preimmune sera and
sera raised against an irrelevant P. falciparum GST-fusion
protein showed no inhibition in the growth of the parasites.
Cultures without any IgG and with sera raised against GST
protein showed normal growth (data not shown). 4–6 inde-
pendent experiments were performed for each treatment, and
2 A. Goswami and S. Sharma, unpublished data.
FIG. 5. In vitro growth inhibition assay. Panel A shows the effect
of purified IgG from rabbit polyclonal antibodies against PfP0-N either
in the presence (f) or absence (l) of human monocytes on the growth of
48-h in vitro culture of P. falciparum FCK2 strain. Preimmune sera
with (M) or without (E) human monocytes and an antibody against
irrelevant GST-fusion protein () were used as controls. Panel B shows
the comparison of the percentage of rings (), trophozoites (E), and
schizonts (M) present at different time points during the same in vitro
growth inhibition assay described in panel A, and in the presence of
monocytes, The top panel shows the distribution of substages in the
presence of control preimmune sera, and the lower panel shows the
substages in the presence of rabbit anti-PfP0-N antibody.
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the figure represents an average of these experiments. The
presence of monocytes were found to stimulate the parasite
growth, but the inhibition of growth of P. falciparum by the
antibody was independent of the presence of monocytes (Fig.
5A).
The growth inhibition studies were assayed by microscopi-
cally counting at least 10,000 red blood cells for each time
point. The counting assay was performed rather than the hy-
poxanthine-uptake assay, because the uptake of hypoxanthine
by the monocytes would cause errors in the assay. Also, start-
ing with a synchronized culture and counting the different
substages at every time point would show the development of
the substages of the parasite with time. Cultures with synchro-
nized ring stages were the starting point, and every 6 h the
different substages of the parasite were counted. In the pres-
ence of the control antibody, the parasites progressed through
the ring, trophozoite, and schizont stages in about 24 h, and
subsequently there was an increase in the ring stages, indicat-
ing the invasion of fresh red blood cells (Fig. 5B, top panel).
However, in the presence of anti-PfP0 antibody, even though
the parasites developed from rings to trophozoite and schizont
stages, fresh infection of red blood cells did not take place as the
number of ring stages remained close to zero until 48 h in
culture (Fig. 5B, lower panel). The same profile was observed
for the distribution of the parasite substages irrespective of the
presence (Fig. 5B) or absence (data not shown) of monocytes.
DISCUSSION
Earlier we had reported the cloning of the full-length gene of
PfP0 from the 7G8 strain of P. falciparum (7). The largest
cDNA clone had a coding region 957 bases long, an unusually
long 59-untranslated region of at least ;1.4 kb, and a 39-un-
translated region of ;50 bases, making it a total of at least
;2.4 kb in size. The 3.0-kb transcript therefore matches with
this size. It is not clear whether the second transcript of
;2.0-kb size is a processed transcript or a degradation product.
The transcripts are twice as abundant in the trophozoite
stages, indicating that the expression of this gene may be
regulated.
The predicted molecular mass of the full-length gene se-
quence is 37.5 kDa. The rabbit sera raised against the recom-
binant protein domain of the P0 gene recognized a 38-kDa P.
falciparum protein from both 35S- and 32P-labeled cultures,
which matches with the expected size of the deduced P0 pro-
tein. The monospecific immune sera also recognized the same
size protein. These immunoprecipitation studies showed that
the antibodies raised against the PfP0-N recognize a protein of
the predicted size, that it is indeed a phosphoprotein, and that
antibodies against PfP0-N are present among malaria-immune
people and not in patients.
The P0 protein was first identified as a member of the P
family of proteins through coprecipitation studies using anti-
bodies against the conserved carboxyl-terminal region (9, 15).
Although definitive studies have been performed to demon-
strate that P1 and P2 are phosphoproteins (27), there has been
no direct evidence that P0 is a phosphoprotein. 32P-Labeled
cultures of yeast cells showed a large number of phosphoribo-
proteins (28), of which the 41-kDa protein has been assumed to
be the P0 protein (9). Thus, for the first time, through immu-
noprecipitation studies using anti-P0 antibodies, we are dem-
onstrating that P0 is indeed a phosphoprotein.
Autoantibodies against the conserved carboxyl-terminal do-
main of the P proteins have been found in 10–15% of patients
with an autoimmune disorder, systemic lupus erythematosus
(15). These autoantibodies have been implicated as a cause for
the psychotic disorders among these patients. Immune re-
sponse has also been documented against P0 protein in chronic
Chagas’ disease (16) and leishmaniasis (17). However, in each
of these cases the reactivity has been reported against the
carboxyl-terminal domain. The systemic lupus erythematosus
patient sera have been tested for reactivity against the amino-
terminal domain of the P2 protein but did not show any re-
sponse (15). The reactivity of the malaria-immune sera to P0 is
widespread (87% of immune sera samples) (6) and is directed
toward the Pf4 region which is the amino-terminal domain of
the PfP0 protein (7). Thus this immune response toward P0 in
malaria-immune persons appears to be different from that
observed for the systemic lupus erythematosus patients.
The mechanism of the passive clearance of the parasites in
malaria patients with IgG of malaria-immune persons is not
clearly understood. The IgG may be specifically interacting and
blocking crucial parasite domains, or it may be attaching to the
parasitized cells and allowing other cellular components of the
immune system to clear the parasites. The latter has been
supported by studies in which a pool of immune human sera
inhibited the in vitro growth of P. falciparum only in the
presence of monocytes (2). However, these experiments were
performed with mixed specificities of immunoglobulins. Anti-
PfP0-N antibody inhibits the growth of P. falciparum irrespec-
tive of the presence or absence of monocytes, indicating a direct
block of parasite invasion. The mechanism behind the inhibi-
tion of the P. falciparum growth with anti-PfP0-N antibodies is
unclear given the predominant cytoplasmic localization of the
PfP0 protein. The inhibition is unlikely to be due to the inhi-
bition of the P. falciparum ribosomal activity as the develop-
ment from the ring to the schizont stages were nearly normal in
the presence of anti-PfP0-N antibody over a period of 24 h. The
growth inhibition by anti-PfP0-N IgG clearly seems to act at
the erythrocyte-invasion step. While the IFA results do indi-
cate a surface component in addition to the cytoplasmic local-
ization of P0 in the trophozoites and gametocytic stages,
whether there is a surface localization of this protein in the
merozoite stage is yet to be determined. Interestingly, the
presence of an antigenic determinant related to the carboxyl-
terminal of P0 protein has been localized to the surface of
hepatoma, neuroblastoma, and human fibroblast cells (29).
What this surface determinant of P0 protein may be and what
role it may play in the erythrocyte invasion by the malarial
parasite remains to be established.
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